Image

5 Year Result of CCCG-ALL-2015 & Dasatinib VS  Imatinib in the treatment of Paediatric Ph+ acute Lymphoblastic Leukaemia

Topic 1:  5 years result of CCCG-ALL-2015

Topic 2:  Dasatinib VS  Imatinib in the treatment of pediatric Ph+ acute lymphoblastic leukemia

 

Synopsis

 

OBJECTIVE To determine whether dasatinib given at 80 mg/m2 is more effective than imatinib at 300 mg/m2 to improve event-free survival of children with Philadelphia chromosome-positive ALL, in the context of intensive chemotherapy without prophylactic cranial irradiation.

We analyzed the data in our recently completed China Children’s Cancer Group ALL-2015 protocol (CCCG-ALL-2015) which totally omitted prophylactic cranial irradiation and included all acute lymphoblastic leukemia (ALL) patients without exclusion any high-risk subgroups. The 5-year event-free survival was 80.3% for 7640 consecutive patients treated on CCCG-ALL-2015 protocol between 2015 and 2019, and overall survival 91.1%. The cumulative risk of isolated CNS relapse was 1.9%, and any CNS relapse 2.7%. The isolated CNS relapse rate was significantly lower in patients with B-ALL than in those with T-ALL. Independent risk factors for isolated CNS relapse included male sex, the presence of BCR–ABL1 fusion in B-ALL, and presenting leukocyte count ≥50×109/L in T-ALL. Significantly lower isolated CNS relapse was associated with the use of total intravenous anesthesia during intrathecal therapy and flow cytometry examination of diagnostic cerebrospinal fluid among patients with B-ALL.

 

 

Speakers

 

Dr Tang Jing Yan, MD, Ph.D
Department of Hematology/Oncology
Shanghai Children’s Medical Center
Key Laboratory of Pediatric Hematology & Oncology of China Ministry of Health
Shanghai Children's Medical Center
Shanghai, China

 

Dr Shen Shu Hong, MD, Ph.D
Department of Hematology and Oncology
Shanghai Children's Medical Center
Shanghai Jiaotong University School of Medicine
Key Laboratory of Pediatric Hematology & Oncology of China Ministry of Health
National Children’s Medical Center
Shanghai, China

 

Dr Cai Jiao Yang, MD. Ph.D
Attending physician
Department of Hematology and Oncology
Shanghai Children's Medical Center
Shanghai, China

 

Registration

If you wish to register, you may do so here